BRIEF—Oxford BioTherapeutics outlicenses antibody to Genmab

Oxford BioTherapeutics has out-licensed to Genmab a novel antibody which forms part of its program of research in immuno-oncology.

The asset originates from the firm’s proprietary OGAP drug discovery platform, which incorporates a large proteomic database and integrates clinical, experimental and other data.

Genmab will be responsible for the future development and commercialization, and will make an undisclosed upfront payment.

The Danish company will also make payments if certain development and regulatory milestones are met, and pay royalties on any future product sales.

Oxford BioTherapeutics chief executive Christian Rohlff said: “This licensing deal enables OBT to add further depth and momentum into its drug pipeline by having this innovative asset developed by a partner.”